Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

red blood cells model CLL | image credit: digitalpochi - stock.adobe.com
B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds

September 4th 2024

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.

Skin cancer is a dangerous morbidity risk in patients with CLL | image credit: Ocskay Mark - stock.adobe.com
Study Implicates AXL in Skin Cancer Development in CLL

August 26th 2024

CLL cells | image credit: Arif Biswas - stock.adobe.com
Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

August 19th 2024

CLL | Image Credit: Saiful52-stock.adobe.com
New Model Offers Indicators of Ibrutinib Response in CLL

August 16th 2024

DNA helix inside blood drop | Image credit: Елена Бутусова - stock.adobe.com
NGS-Based Risk Stratification, Treatment Shows Cost-Effectiveness in CLL

August 12th 2024

More News

Chronic lymphocytic leukemia - LASZLO - stock.adobe.com
January 12th 2024

Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL

Rose McNulty
A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
Chronic lymphocytic leukemia in blood | Image credit: LASZLO - stock.adobe.com
January 10th 2024

Zanubrutinib Shows Benefits Over Bendamustine Plus Rituximab Across CLL/SLL Subgroups

Rose McNulty
Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
Image credit: jarun011 - stock.adobe.com
January 5th 2024

Risk of Richter Transformation in CLL May Be Lower in Novel Agent Era

Rose McNulty
An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.
CLL Society’s Koffman Says ASH 2023 Offered “Evolutionary” Changes
January 2nd 2024

CLL Society’s Koffman Says ASH 2023 Offered “Evolutionary” Changes

Interview by Mary Caffrey
Jaypirca | Image credit: Eli Lilly
December 2nd 2023

FDA Grants Accelerated Approval to Pirtobrutinib for Patients With CLL/SLL After Use of BTK, BCL-2 Inhibitors

Mary Caffrey
The therapy is already approved for certain patients with relapsed/refractory mantle cell lymphoma.
Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy
August 3rd 2023

Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy

Mary Caffrey
Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.
Health data on computer
June 11th 2023

Researchers Deliver Updates on Efforts Toward Eradicating CLL

Christina Mattina
Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.
Balancing pros and cons
June 10th 2023

Long-Term Data Show QOL Advantage of Zanubrutinib in 3 Cancers

Christina Mattina
Results from the ASPEN and ALPINE trials of zanubrutinib showed greater improvements in quality of life (QOL) vs ibrutinib.
<123

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo